Trial Profile
Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Mometasone (Primary) ; Oxymetazoline (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Schering-Plough
- 26 Mar 2010 Results were presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 02 Mar 2010 QOL results presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 02 Mar 2010 Results were presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.